BICO Group AB (publ)

$ 16.70 4.51 %

BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.

CEO: Maria Forss - https://bico.com

Price objectif

-

Recommandation

-

DCF

$ -7.05

Loading data...

BICO.ST vs S&P500

Loading data...

No data available.

Quick ratio

1.99

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-0.80

may indicate that the company is undervalued or has poor growth prospects.

EPS

-20.92

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-51.81 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-9.82 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

16.20

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.43

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.34

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
-3.02 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.34 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.23 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.